Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease

    June 2025 in “ Dermatopathology ”
    Aya Fadel, Jayakumar Nithura, Zahraa F. Saadoon … Hussain Hussain
    Studysummary This study reports that SARS-CoV-2 infection, COVID-19 vaccination, and off-label dupilumab treatment may exacerbate psoriasis, with overlapping inflammatory pathways involving cytokines like IL-17 and TNF-α. Histopathological similarities between psoriasis flares and COVID-19 skin manifestations were noted, suggesting a potential connection requiring further research.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Dermatologic Changes in Experimental Model of Long COVID Microorganisms · 2024
    2. Dupilumab in Inflammatory Skin Diseases: A Systematic Review Biomolecules · 2023